Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice

Explore key trial results and emerging treatment strategies for your patients with TNBC in this CME-certified, expert-authored module and downloadable PowerPoint slideset.
Sara Hurvitz, MD, FACP


Sara Hurvitz, MD, FACP, provides her expert perspective on leveraging the latest clinical trial results for customized treatment of metastatic TNBC based on patient and disease characteristics.

Sara Hurvitz, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 14, 2017 Expiration: November 13, 2018

Downloadable Slideset

In this downloadable slideset, Sara Hurvitz, MD, FACP, discusses the latest clinical data for optimal treatment of metastatic TNBC, and highlights promising agents under investigation.

Released: November 14, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?